TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who require moderate procedural sedation with propofol in the ED~Exclusion Criteria:~* age \> 17 years~* pregnant~* intoxicated~* cannot give informed consent~* allergy to ketamine or propofol~* patient will require deep procedural sedation~* ASA physical status score \> 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
- Ketamine (Type: ACTIVE_COMPARATOR): ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in good health~* Subject is a nonsmoker~* Subject is willing to comply with the study restrictions~Exclusion Criteria:~* Subject has a history of any illness that might confound the results of the study or might make participation in the study unsafe~* Subject has a history of stroke, seizures, or major neurological disorder~* Subject has a history of cancer~* Subject consumes more than two alcoholic drinks per day~* Subject consumes more than three caffeinated beverages daily

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): aprepitant 165 mg
- 2 (Type: ACTIVE_COMPARATOR): aprepitant 185 mg
- 3 (Type: EXPERIMENTAL): fosaprepitant 150 mg
- 4 (Type: EXPERIMENTAL): aprepitant with food

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Repletion in Chronic Cough and Iron Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Unexplained cough : no detectable trigger for chronic cough identified, such as persistent rhinitis, chronic sinusitis, gastroesophageal reflux disease and asthma.~* no benefit by prior treatment with antiH1-histaminic drug and proton pump inhibitor.~* iron deficiency.~* normal lung function tests and chest radiography no relevant systemic disease.~* no acute respiratory infection in the last eight weeks.~* no pharmacological treatment in the last two weeks.~Exclusion Criteria:

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* blood loss from obstetric hemorrhage \>= 1000 mL~* pulse \> 100 beats per minute or systolic blood pressure \< 100 mmHg~Exclusion Criteria:~Absolute exclusion criteria:~* current viable third trimester intrauterine pregnancy that can be delivered in the next 20 minutes after hemorrhage begins~* current bleeding sites above the diaphragm.~Relative exclusion criteria:~* history or current clinical evidence of mitral stenosis or congestive heart failure (CHF)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-Intervention (Type: NO_INTERVENTION): The Pre-Intervention Phase served as the Control / Baseline group.
- Post-Intervention (Type: EXPERIMENTAL): Intervention used in this phase and outcomes compared to the Pre-Intervention phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \< 18 years old~* Assessed and/or listed for heart, kidney, liver transplantation~* Planned oral or enteral maintenance immunosuppression with tacrolimus post transplant~* Informed consent of legal guardian~Exclusion Criteria:~* Contra-indications to oral or enteral tacrolimus~* Co-morbidities that preclude standard dosing e.g. significant renal or hepatic insufficiency~* Participation in other investigational drug trials within 30 days of study initiation

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Standard Dosing Arm (Type: ACTIVE_COMPARATOR): Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
- Pharmacogenetic Arm (Type: EXPERIMENTAL): Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Is Vitamin D2 Treatment-associated Decrease in 25(OH)D3 Level a Reciprocal Phenomena?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* non-pregnant adults (age ≥18 years)~* healthy~* total 25(OH)D level between 20 to 65 nmol/L.~* living in Riyadh area~Exclusion criteria:~* consumption of more than one serving of milk daily~* taking vitamin D supplements~* habitual weekly sun exposure of 10 hours or more~* history of granulomatous, liver, or kidney disease~* taking anticonvulsants, barbiturates, or steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group-2-D3 (Type: EXPERIMENTAL): Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
- Group-2-Placebo (Type: PLACEBO_COMPARATOR): Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
- Group-1-D2 (Type: EXPERIMENTAL): Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
- Group-1-Placebo (Type: PLACEBO_COMPARATOR): Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the Nanodropper Device on Pupillary Dilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants under the age of 18 years old~Exclusion Criteria:~* Participants 18 years and older~* Pupillary or anterior segment abnormality~* Participants with pre-existing health conditions that would prevent pupillary dilation.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pediatric Participant's Eyes Using Standard Pupilary Dilation (Type: ACTIVE_COMPARATOR): Consenting pediatric participants will undergo standard pupillary dilation in one eye.
- Pediatric Participant's Eyes using Nanodropper attachment (Type: EXPERIMENTAL): Consenting pediatric participants will undergo pupillary dilation in the second eye using the Nanodropper attachment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of mild to moderate essential hypertension (sitting diastolic blood pressure \>= 90 and \< 110 and/or sitting systolic blood pressure \>= 140 and \< 180)~* Diagnosis of obesity (Body Mass Index \>= 27 and \< 50 and steady body weight)~* Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test)~Exclusion Criteria:~* Prior exposure or known contraindication or hypersensitivity to topiramate~* Pregnancy, nursing or subjects who plan to become pregnant during the study~* Diagnosis of severe hypertension~* History or diagnosis of Diabetes Mellitus~* A history of diastolic or systolic hypertension secondary to a known cause~* Significant cardiovascular or liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female infants, 8 to 16 weeks of age at the time of the first vaccination.~Exclusion Criteria:~* Previous vaccination against OR history of OR exposure since birth to diphtheria, pertussis, tetanus, polio, hepatitis B, Hib and/or meningococcal disease.~* Planned administration/administration of a vaccine not foreseen in the study since birth.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* A family history of congenital or hereditary immunodeficiency.~* History of any neurologic disorders or seizures, allergic disease or reactions likely to be exacerbated by any component of the vaccine

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 16 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2010; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted~* Current or former cigarette smokers~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit~* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1~* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness~* History or presence of asthma verified from medical records~* Chronic use of oxygen therapy greater than or equal to 15 hours per day~* Patient with uncontrolled infection due to HIV and/or active hepatitis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics~* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium Bromide 200 µg (Type: EXPERIMENTAL): aclidinium bromide, inhaled, 52 weeks of treatment
- Aclidinium Bromide 400 µg (Type: EXPERIMENTAL): aclidinium bromide, inhaled, 52 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, 18 years or older, requiring elective, primary or repeat vascular procedures with at least one end-to-side femoral or upper extremity vascular access arterial anastomosis (e.g. femoral-femoral, femoral-popliteal, femoral-tibial, ilio-femoral, aorto-bifemoral, abdominal aortic aneurysm, upper extremity vascular access for dialysis) using uncoated or heparin-coated PTFE grafts and polypropylene sutures (size 5-0 or 6-0) with a 1:1 needle-to-thread ratio.~* Following initial arterial clamp release, the study surgeon determines that adjunctive measures are needed to obtain haemostasis at the SAS.~* Subjects must be willing to and capable of participating in the study, and provided written informed consent.~Exclusion Criteria:~* Subjects undergoing re-vascularisation using autologous conduits (e.g. saphenous vein) or prosthetic material other than uncoated or heparin-coated PTFE.~* Subjects undergoing emergency surgery.~* Subjects with any intra-operative findings that may preclude conduct of the study procedure.~* Subjects with known intolerance to heparin, blood products or to one of the components of the study product.~* Subjects unwilling to receive blood products.~* Subjects with autoimmune immunodeficiency diseases (including known HIV).~* Subjects who are known, current alcohol and / or drug abusers.~* Subjects who have participated in another investigational drug or device research study within 30 days of enrolment.~* Female subjects who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-70 years of age;~* rheumatoid arthritis for \>= 6 months;~* receiving permitted DMARDs, at a stable dose, for \>= 8 weeks prior to baseline;~* current inadequate clinical response to DMARDs.~Exclusion Criteria:~* major surgery, including joint surgery, within 8 weeks before entering study, or planned major surgery within 6 months following randomization;~* rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;~* unsuccessful treatment with an anti-TNF agent;~* previous treatment with tocilizumab.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject completed study M02-518 or M02-570~Exclusion Criteria:~* Subject prematurely discontinued study M02-518 or M02-570~  * Female subject who is pregnant or breast-feeding or considering becoming pregnant~ * Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin.~* Fasting LDL-C \> 70 mg/dL and triglyceride \<=400 mg/dL.~* High or very high risk of incurring a cardiovascular event.~Exclusion Criteria:~* Pregnant or breastfeeding females.~* Cardiovascular or cerebrovascular event of procedures during the past 30 days.~* Congestive heart failure NYHA class IV.~* Poorly controlled hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615;RN316) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Mechanism of rTMS in Children With ASD: an Open-label Clinical Trial(Ⅱ)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged ≥4 years.~* Meeting the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Edition 5 (DSM-5) .~* Confirmed by the ADOS and/or ADI-R diagnostic tool.~* Informed consent.~Exclusion Criteria:~* Patients with metal implants .~* Patients with neurological diseases such as epilepsy .~* Patients requiring surgical treatment due to structural abnormalities indicated by brain MRI .~* Genetic or chromosomal abnormalities .~* Suffering from mental disorders (such as mood disorders, etc.)~* Suffering from serious heart disease .~* Hearing-impaired .~* Intracranial hypertension .~* Participating in other clinical trials.~* Participants who received other interventions within 4 weeks prior to enrollment.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- rTMS Group (Type: EXPERIMENTAL): Participants will receive cTBS over the left primary motor cortext (M1) for 5 consecutive days. The detailed parameters as follows: 80% of RMT, 60 cycles of 10 bursts of three pulses at 50 Hz were delivered in 2-second trains (5 Hz) with no intertrain interval (i.e. triplet standard cTBS, 1800 pulses, 120s). Stimulation sessions were delivered hourly, 10 sessions were applied per day (18,000 pulses/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Open angle glaucoma~Exclusion Criteria:~* Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular disorders.~* Functionally significant visual field loss, including severe nerve fiber bundle defects.~* Prior glaucoma surgery.~* Uncontrolled systemic disease, pregnant females or those planning a pregnancy.~* Other ocular status conditions, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Travoprost Intraocular Implant, high elution (Type: EXPERIMENTAL): This implant will be surgically implanted and elute travoprost, a prostaglandin.
- Travoprost Intraocular Implant, low elution (Type: EXPERIMENTAL): This implant will be surgically implanted and elute travoprost, a prostaglandin.
- Timolol Maleate Ophthalmic Solution, 0.5% (Type: ACTIVE_COMPARATOR): Timolol, a beta blocker, will be dosed twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete